Treace Medical Concepts Inc

Treace Medical Concepts Inc

TMCI · NASDAQ · Healthcare / Medical Devices

5.27USD-0.07 (-1.31%)

Price History

Full chart

Market Stats

Previous Close5.34
Open5.32
Day Range4.95 – 5.32
52-Week Range1.17 – 7.08
Volume287.32K
Market Cap292.66M
P/E (TTM)0.00
Forward P/E0.00
EPS-0.92
Dividend Yield0.00%
Beta1.41
50-Day Avg4.50
200-Day Avg3.03

About

Treace Medical Concepts, Inc., a medical technology company, designs, manufactures, and markets medical devices in the United States. The company offers Lapiplasty System, enables surgeons to correct all three dimensions of the bunion deformity, stabilize the first TMT joint, and allow return to weight-bearing in a walking boot; minimally invasive products for four bunion classes; Nanoplasty 3D Minimally Invasive Bunion Correction System delivers a reproducible 3D correction of the bunion deformity through a cosmetically appealing; and Percuplasty Percutaneous 3D Bunion Correction System that provides 3D correction of the bunion deformity through percutaneous incisions. It also provides Adductoplasty System, a system designed for the correction of metatarsus adductus deformities and osteoarthritis of the midfoot; SpeedMTP Rapid Compression Implant; SpeedPlate Implant Fixation Platform to address the fusion of larger bones of the midfoot and rearfoot; SpeedPlate Micro-Quad implant, an implant designed for stability and fit in small incision surgical approaches; and SpeedAkin Anatomic Compression Implant. In addition, the company offers The IntelliGuide patient specific instrumentation provides patient-specific, 3D-printed cut guides, and a pre-operative plan for a complete picture of the deformity and correction. Further, it provides FastGrafter Autografter Harvesting System; SpeedRelease Guided Release Instrument; TriTome Triple-Edge Release Instrument; RazorTome 7mm Precision Osteotome; LapiTome Hooked Bone Removal Osteotome; GreatRelease Rapid MTP Release Instrument; CornerChisel Release Tool; NanoRasp MIS Bone Contouring Tool; FeatherRasp Rapid Bone Contouring Instrument; and Akinator Single-cut Akin Wedge Osteotomy tool. Additionally, the company offers biologics and wedges, such as Treace Allograft Wedges; and CortiFuse Flowable Cortical Fibers. Treace Medical Concepts, Inc. was founded in 2013 and is headquartered in Ponte Vedra, Florida.

Company Details

  • SectorHealthcare
  • IndustryMedical Devices
  • CEOMr. John T. Treace
  • Employees450
  • Headquarters100 Palmetto Park Place, Ponte Vedra, FL, United States, 32081, USA
  • Websitehttps://www.treace.com

Leadership

  • Mr. John T. TreaceFounder, Chairman & CEO · b. 1972
  • Mr. Mark L. Hair CPAChief Financial Officer · b. 1970
  • Mr. Scot M. Elder J.D.Chief Legal & Compliance Officer and Corporate Secretary · b. 1975
  • Dr. Sean F. Scanlan Ph.D.Chief Innovation & Marketing Officer · b. 1982
  • Mr. Terry W. LubbenChief Operations & Supply Chain Officer · b. 1965
  • Mr. Zac PotterSenior VP & Chief Accounting Officer
  • Mr. Taylor EricksonChief Information & Cybersecurity Officer
  • Mr. Brad BarrSenior Vice President of Sales
  • Mr. Daniel E. OwensChief Human Resources Officer · b. 1972
  • Ms. Shana ZinkSenior Vice President of Clinical Affairs & Reimbursement

Financials

Income Statement

Currency: USD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue39.42M57.37M94.42M141.84M187.12M209.36M212.69M
Growth (%)-+45.54%+64.59%+50.22%+31.92%+11.89%+1.59%
Cost of Revenue7.63M12.47M16.89M27.52M35.18M41.09M42.94M
Gross Profit31.79M44.90M77.53M114.31M151.94M168.26M169.75M
Gross Margin80.64%78.26%82.11%80.60%81.20%80.37%79.81%
Operating Expense35.32M44.04M94.04M149.16M203.37M223.95M223.91M
Operating Income-3.54M855.00K-16.51M-34.84M-51.43M-55.69M-54.15M
Operating Margin-8.97%1.49%-17.49%-24.57%-27.48%-26.60%-25.46%
EBITDA-2.63M2.06M-15.81M-36.28M-39.01M-42.07M-43.18M
EBITDA Margin-6.67%3.60%-16.74%-25.58%-20.85%-20.09%-20.30%
Net Income-4.26M-3.67M-20.55M-42.81M-49.53M-55.74M-59.00M
Net Income Margin-10.82%-6.39%-21.77%-30.19%-26.47%-26.63%-27.74%
R&D5.07M5.85M10.20M13.58M15.44M20.59M20.28M
R&D as % of Total Revenue12.86%10.19%10.81%9.58%8.25%9.83%9.54%
Interest Expense841.00K4.52M4.06M4.40M5.17M5.26M5.32M
Interest Expense % of Total Revenue2.13%7.88%4.30%3.10%2.76%2.51%2.50%

Balance Sheet

Currency: USD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets29.72M41.81M140.82M159.02M251.91M217.09M190.58M
Total Liabilities26.55M41.03M47.75M98.50M113.97M104.20M103.25M
Total Equity3.16M776.00K93.07M60.53M137.94M112.89M87.33M
Cash12.14M18.08M105.83M19.47M12.98M11.35M10.71M
Total Debt19.22M30.98M29.36M68.59M70.30M69.65M13.98M
Net Debt7.08M12.90M-76.47M49.12M57.32M58.30M3.27M

Cash Flow

Currency: USD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-7.67M-4.49M-17.19M-30.65M-34.58M-37.17M-15.97M
Investing Cash Flow-1.21M-1.07M-2.71M-76.52M-81.30M35.38M13.25M
Financing Cash Flow19.74M11.50M107.65M20.81M109.38M160.00K2.08M
Capital Expenditure1.21M1.07M2.71M14.84M11.46M11.59M13.52M
Free Cash Flow-8.88M-5.56M-19.90M-45.49M-46.03M-48.76M-29.49M
Dividends Paid--7.93M-000
FCF to OCF115.78%123.79%115.73%148.41%133.14%131.19%184.64%
Dividend Paid to FCF---39.88%-0.00%0.00%0.00%

Earnings

Report DateMar 31, 2020Mar 3, 2021May 25, 2021Aug 5, 2021Nov 4, 2021Mar 3, 2022May 5, 2022Aug 9, 2022Nov 8, 2022Mar 7, 2023May 8, 2023Aug 8, 2023Nov 9, 2023Feb 27, 2024May 7, 2024Aug 6, 2024Nov 5, 2024Feb 25, 2025May 8, 2025Aug 7, 2025Nov 6, 2025Feb 26, 2026May 8, 2026Aug 7, 2026Nov 5, 2026
EPS Estimate0.000.00-0.06-0.13-0.11-0.01-0.17-0.19-0.29-0.14-0.24-0.23-0.26-0.09-0.31-0.28-0.26-0.04-0.30-0.29-0.27-0.15-0.31-0.30-0.25
EPS Actual-0.050.06-0.07-0.10-0.12-0.12-0.16-0.23-0.22-0.08-0.23-0.20-0.28-0.10-0.28-0.28-0.25-0.00-0.25-0.28-0.22-0.08-0.28-0.24-
Surprise---16.67%23.08%-9.09%-1968.97%5.88%-21.05%24.14%42.86%4.17%13.04%-7.69%-11.11%9.68%0.00%3.85%96.25%16.67%3.45%18.52%48.52%9.68%20.00%-
Timing--After-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hours-Pre-marketPre-marketPre-market

Key Statistics & Ratios

Market Cap292.66M
Enterprise Value320.05M
Trailing P/E0.00
Forward P/E0.00
Price / Sales1.43
Price / Book4.33
EPS-0.92
Book Value1.04
Revenue (TTM)205.31M
Gross Profit (TTM)163.12M
EBITDA-46.35M
Profit Margin-28.99%
Operating Margin-32.97%
Return on Equity-71.99%
Return on Assets-17.33%
Shares Outstanding65.03M
Shares Float47.84M
Beta1.41
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Buy
Based on 7 analystsTarget 5.50
  • Strong Buy
    2
  • Hold
    5

Ownership Breakdown

Institutions
49.67%
Insiders
25.27%
Retail / Other
25.06%

Top Institutional Holders

  • Armistice Capital, LLC
    6.36M9.79%
  • BlackRock Inc
    3.34M5.14%
  • Bank of America Corp
    3.21M4.94%
  • Gagnon Securities LLC
    3.03M4.66%
  • Gagnon Advisors, LLC
    1.53M2.36%
  • Vanguard Capital Management, LLC
    1.46M2.25%
  • State Street Corp
    1.24M1.90%
  • CIBC Bancorp USA Inc.
    1.22M1.87%
  • AQR Capital Management LLC
    1.06M1.63%
  • Geode Capital Management, LLC
    1.01M1.55%
  • Acadian Asset Management LLC
    941.29K1.45%
  • Millennium Management LLC
    738.63K1.14%
  • Weber Capital Management LLC
    589.62K0.91%
  • D. E. Shaw & Co LP
    583.28K0.90%
  • UBS Group AG
    542.90K0.83%
  • Renaissance Technologies Corp
    522.90K0.80%
  • Citadel Advisors Llc
    516.99K0.80%
  • Vanguard Portfolio Management, LLC
    435.89K0.67%
  • Northern Trust Corp
    405.90K0.62%

Top Fund Holders

  • Vanguard MStar Total Stk Mkt Idx Invest
    1.45M2.23%